A solid dispersion comprises, in essentially non-crystalline form, a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a cancer.本發明係關於一種固體分散劑，其包含基本上呈非結晶形式分散於固體基質中之激酶抑制化合物(例如，N-(4-{4-胺基-7-[1-(2-羥基乙基)-1H-吡唑-4-基]噻吩并[3,2-c]吡啶-3-基}苯基)-N'-(3-氟苯基)脲)，該固體基質包含(a)醫藥上可接受之水溶性聚合物載劑及(b)醫藥上可接受之表面活性劑。本發明亦係關於製備此一固體分散劑之方法，其包含將該化合物、該聚合物載劑及該表面活性劑溶於適宜溶劑中，及去除該溶劑，以提供固體基質，該固體基質包含該聚合物載劑及該表面活性劑，且具有該基本上呈非結晶形式分散於其中之化合物。該固體分散劑適於經口投與至有需要的個體，用於治療癌症。
